Ph.D., Director, R&D, Integrated Oncology, LabCorp
Biography
After studying in the field of cancer epigenetics, Dr. Jensen joined Sequenom in 2009 and was part of the team that developed and launched the first commercially available noninvasive prenatal test based on circulating cell-free DNA (cfDNA) in the U.S. Subsequently, Dr. Jensen has been involved in numerous assay development efforts focused on the identification and detection of genetic and epigenetic changes in cfDNA for use in prenatal and cancer diagnostics. Since the acquisition of Sequenom by LabCorp in 2016, his work has been primarily focused on the development of novel technologies and assays, primarily using cfDNA, with the overarching goal of utilizing these technologies to improve human health.
Liquid Biopsy Showcase:
LabCorp
Integrated Oncology is the segment of LabCorp that is committed to serving cancer patients through an array of pathology and oncology testing services.
Genome-Wide cfDNA Sequencing In Cancer Patients
An assay using low-coverage, genome-wide sequencing of cell-free DNA was developed and utilized to monitor therapeutic response in cancer patients. In this presentation, we will present data further describing the utility of the assay and potential improvements thereof.
Session Abstract – PMWC 2020 Silicon Valley
Track 7 - January 23 9.00 A.M.-1.15 P.M.
The PMWC 2020 Liquid Biopsy Showcase will provide a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).
